The University of Queensland

Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound

Lu, Cathy, Rosentreter, Ryan, Delisle, Maxime, White, Mattie, Parker, Claire E., Premji, Zahra, Wilson, Stephanie R., Baker, Mark E., Bhatnagar, Gauraang, Begun, Jakob, Bruining, David H., Bryant, Robert, Christensen, Britt, Feagan, Brian G., Fletcher, Joel G., Jairath, Vipul, Knudsen, John, Kucharzik, Torsten, Maaser, Christian, Maconi, Giovanni, Novak, Kerri, Rimola, Jordi, Taylor, Stuart A., Wilkens, Rune, Rieder, Florian and The Stenosis Therapy and Anti‐Fibrotic Research (STAR) consortium (2024). Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound. Alimentary Pharmacology & Therapeutics, 59 (8), 928-940. doi: 10.1111/apt.17918

Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero

Prentice, Ralley, Flanagan, Emma, Wright, Emily K., Gibson, Peter R., Rosella, Sam, Rosella, Ourania, Begun, Jakob, An, Yoon-Kyo, Lawrance, Ian C., Kamm, Michael A., Sparrow, Miles, Goldberg, Rimma, Prideaux, Lani, Vogrin, Sara, Kiburg, Katerina V., Ross, Alyson L., Burns, Megan and Bell, Sally J. (2024). Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2024.02.025

Cannabidiol - help and hype in targeting mucosal diseases

Moniruzzaman, Md, Janjua, Taskeen Iqbal, Martin, Jennifer H., Begun, Jakob and Popat, Amirali (2024). Cannabidiol - help and hype in targeting mucosal diseases. Journal of Controlled Release, 365, 530-543. doi: 10.1016/j.jconrel.2023.11.010

P034 Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial

Davies, J, Amiss, A, Khoo, E, An, Y K and Begun, J (2024). P034 Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial. Journal of Crohn's and Colitis, 18 (Supplement_1), i292-i292. doi: 10.1093/ecco-jcc/jjad212.0164

P854 Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

Khoo, E, Amiss, A, Ding, J N, Bryant, R, Mohsen, W, Connor, S, Leung, R, Croft, A, Lynch, K, Sparrow, M, De Cruz, P, An, Y K, Holtmann, G and Begun, J (2024). P854 Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. Journal of Crohn's and Colitis, 18 (Supplement_1), i1583-i1583. doi: 10.1093/ecco-jcc/jjad212.0984

Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment

Khoo, Emi, Lee, Andrew, Neeman, Teresa, An, Yoon‐Kyo and Begun, Jakob (2023). Comprehensive systematic review and pooled analysis of real‐world studies evaluating immunomodulator and biologic therapies for chronic pouchitis treatment. JGH Open, 7 (12), 899-907. doi: 10.1002/jgh3.13000

Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study

Peyrin-Biroulet, Laurent, Allegretti, Jessica R., Rubin, David T., Bressler, Brian, Germinaro, Matthew, Huang, Kuan-Hsiang (Gary), Shipitofsky, Nicole, Zhang, Hongyan, Wilson, Rebbecca, Han, Chenglong, Feagan, Brian G., Sandborn, William J., Panés, Julian, Hisamatsu, Tadakazu, Lichtenstein, Gary R., Sands, Bruce E., Dignass, Axel, Abrahamovych, Orest, Afanasieva, Halyna, Aitova, Lilia, Altintas, Engin, Altwegg, Romain, Andreev, Pavel, Aomatsu, Kazuki, Augustyn, Monika, Balestrieri, Paola, Begun, Jakob, Brunatto, Luciana, Bulgheroni, Diego ... QUASAR Study Group (2023). Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study. Gastroenterology, 165 (6), 1443-1457. doi: 10.1053/j.gastro.2023.08.038

Pre-existing tissue mechanical hypertension at adherens junctions disrupts apoptotic extrusion in epithelia

Mann, Zoya, Lim, Fayth, Verma, Suzie, Nanavati, Bageshri N., Davies, Julie M., Begun, Jakob, Hardeman, Edna C., Gunning, Peter W., Subramanyam, Deepa, Yap, Alpha S. and Duszyc, Kinga (2023). Pre-existing tissue mechanical hypertension at adherens junctions disrupts apoptotic extrusion in epithelia. Molecular Biology of the Cell, 35 (1), br3. doi: 10.1091/mbc.e23-08-0337

MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier

McGuckin, Michael A., Davies, Julie M., Felgner, Pascal, Wong, Kuan Yau, Giri, Rabina, He, Yaowu, Moniruzzaman, Md., Kryza, Thomas, Sajiir, Haressh, Hooper, John D., Florin, Timothy H., Begun, Jakob, Oussalah, Abderrahim, Hasnain, Sumaira Z., Hensel, Michael and Sheng, Yong H. (2023). MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier. Cellular and Molecular Gastroenterology and Hepatology, 16 (6), 985-1009. doi: 10.1016/j.jcmgh.2023.08.011

Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel disease

Ewais, Tatjana, Begun, Jakob and Laakso, E-Liisa (2023). Protocol for a single-arm feasibility study of photobiomodulation for fatigue, depression, and pain in inflammatory bowel disease. Biomedicines, 11 (8) 2179, 1-11. doi: 10.3390/biomedicines11082179

Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis

Gilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115

Upadacitinib induction and maintenance therapy for Crohn's disease

Loftus, Edward V., Panés, Julian, Lacerda, Ana P., Peyrin-Biroulet, Laurent, D'Haens, Geert, Panaccione, Remo, Reinisch, Walter, Louis, Edouard, Chen, Minhu, Nakase, Hiroshi, Begun, Jakob, Boland, Brigid S., Phillips, Charles, Mohamed, Mohamed-Eslam F, Liu, Jianzhong, Geng, Ziqian, Feng, Tian, Dubcenco, Elena and Colombel, Jean-Frederic (2023). Upadacitinib induction and maintenance therapy for Crohn's disease. The New England journal of medicine, 388 (21), 1966-1980. doi: 10.1056/NEJMoa2212728

1029 WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL

Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). 1029 WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL. Gastroenterology, 164 (6), S-221. doi: 10.1016/s0016-5085(23)01488-9

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Feagan, Brian G, Sands, Bruce E, Sandborn, William J, Germinaro, Matthew, Vetter, Marion, Shao, Jie, Sheng, Shihong, Johanns, Jewel, Panés, Julián, Tkachev, Alexander, Kalimullina, Dilara, Petryka, Robert, Osipenko, Marina, Tsarynna, Nataliia, Bilianskyi, Leonid, Kleczkowski, Dariusz, Yurkiv, Andrii, Woynarowski, Marek, Abrahamovych, Orest, Ivanishyn, Olha, Rydzewska, Grazyna, Kierkus, Jaroslaw, Petrova, Elina, Vasilevskaya, Olga, Afanasieva, Halyna, Francesconi, Carlos, Leszczyszyn, Jaroslaw, Bunkova, Elena, Platonov, Dmitry ... for the VEGA Study Group (2023). Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. The Lancet Gastroenterology and Hepatology, 8 (4), 307-320. doi: 10.1016/S2468-1253(22)00427-7

Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver

Alabbas, Saleh Y., Giri, Rabina, Oancea, Iulia, Davies, Julie, Schreibner, Veronika, Florin, Timothy H. and Begun, Jakob (2023). Gut inflammation and adaptive immunity amplify acetaminophen toxicity in bowel and liver. Journal of Gastroenterology and Hepatology, 38 (4), 609-618. doi: 10.1111/jgh.16102

Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer

Lyons, Nicholas, Giri, Rabina, Begun, Jakob, Clark, David A, Proud, David, He, Yaowu, Hooper, John and Kryza, Thomas (2023). Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxidants and Redox Signaling, 39 (1-3), 186-205. doi: 10.1089/ars.2022.0127

An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis

Mortlock, Sally, Lord, Anton, Montgomery, Grant, Zakrzewski, Martha, Simms, Lisa A, Krishnaprasad, Krupa, Hanigan, Katherine, Doecke, James D, Walsh, Alissa, Lawrance, Ian C, Bampton, Peter A, Andrews, Jane M, Mahy, Gillian, Connor, Susan J, Sparrow, Miles P, Bell, Sally, Florin, Timothy H., Begun, Jakob, Gearry, Richard B and Radford-Smith, Graham L. (2023). An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis. Journal of Crohn's and Colitis, 17 (2), 277-288. doi: 10.1093/ecco-jcc/jjac121

P413 Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

Pudipeddi, A, Paramsothy, S, Kariyawasam, V, Paramsothy, R, Ghaly, S, Haifer, C, An, Y K, Begun, J, Connor, S, Corte, C, Ward, M, De Cruz, P, Fung, C, Redmond, D and Leong, R W (2023). P413 Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. Journal of Crohn's and Colitis, 17 (Supplement_1), i542-i543. doi: 10.1093/ecco-jcc/jjac190.0543

Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis

Malloy, Reuben, Fernandes, Richard, Begun, Jakob and An, Yoon-Kyo (2022). Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. BMJ Case Reports, 15 (12) 252140. doi: 10.1136/bcr-2022-252140

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

Panes, Julian, Loftus, Edward, Lacerda, Ana, Peyrin-Biroulet, Laurent, D’Haens, Geert, Panaccione, Remo, Reinisch, Walter, Louis, Edouard, Chen, Minhu, Nakase, Hiroshi, Begun, Jakob, Boland, Brigid, Liu, Jianzhong, Dubcenco, Elena, Mohamed, Mohamed-Eslam, Feng, Tian and Colombel, Jean-Frederic (2022). S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results. American Journal of Gastroenterology, 117 (1), S10-S10. doi: 10.14309/01.ajg.0000897656.25080.34

GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infection

Lamba, M., Tiwari, N., Remedios, M., Begun, J., Christensen, B., Bollipo, S. and Devereaux, B. (2022). GESA Statement on the timing of elective endoscopic procedures in patients with recent COVID-19 infection. Journal of Gastroenterology and Hepatology (Australia), 37 (7), 1400-1401. doi: 10.1111/jgh.15873

MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axis

Sheng, Yong H., Davies, Julie M., Wang, Ran, Wong, Kuan Yau, Giri, Rabina, Yang, Yuanhao, Begun, Jakob, Florin, Timothy H., Hasnain, Sumaira Z. and McGuckin, Michael A. (2022). MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axis. Cellular and Molecular Gastroenterology and Hepatology, 14 (4), 789-811. doi: 10.1016/j.jcmgh.2022.06.010

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Sands, Bruce E, Irving, Peter M, Hoops, Timothy, Izanec, James L, Gao, Long-Long, Gasink, Christopher, Greenspan, Andrew, Allez, Matthieu, Danese, Silvio, Hanauer, Stephen B, Jairath, Vipul, Kuehbacher, Tanja, Lewis, James D, Loftus, Edward V, Mihaly, Emese, Panaccione, Remo, Scherl, Ellen, Shchukina, Oksana B, Sandborn, William J, Afzali, Anita, Aitova, Lilia, Aldeguer i Mante, Xavier, Altorjay, István, Argüelles Arias, Federico, Armuzzi, Alessandro, Augustyn, Monika, Bafutto, Mauro, Barrio, Jesus, Begun, Jakob ... Zdena, Zadorova (2022). Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. The Lancet, 399 (10342), 2200-2211. doi: 10.1016/S0140-6736(22)00688-2

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis

Cheon, Jae Hee, Paridaens, Kristine, Awadhi, Sameer Al, Begun, Jakob, Fullarton, John R, Louis, Edouard, Magro, Fernando, Marquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Dignass, Axel U and Travis, Simon PL (2022). The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 21 (1), 161-167. doi: 10.5217/ir.2022.00006

Secreted NF-κB suppressive microbial metabolites modulate gut inflammation

Giri, Rabina, Hoedt, Emily C., Khushi, Shamsunnahar, Salim, Angela A., Bergot, Anne-Sophie, Schreiber, Veronika, Thomas, Ranjeny, McGuckin, Michael A., Florin, Timothy H., Morrison, Mark, Capon, Robert J., Ó Cuív, Páraic and Begun, Jakob (2022). Secreted NF-κB suppressive microbial metabolites modulate gut inflammation. Cell Reports, 39 (2) 110646, 110646. doi: 10.1016/j.celrep.2022.110646

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

Louis, Edouard, Paridaens, Kristine, Al Awadhi, Sameer, Begun, Jakob, Cheon, Jae Hee, Dignass, Axel U, Magro, Fernando, Márquez, Juan Ricardo, Moschen, Alexander R, Narula, Neeraj, Rydzewska, Grazyna, Freddi, Matthew J and Travis, Simon Pl (2022). Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterology, 9 (1) e000853. doi: 10.1136/bmjgast-2021-000853

Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages

Tran, Thao Thanh, Mathmann, Carmen D., Gatica-Andrades, Marcela, Rollo, Rachel F., Oelker, Melanie, Ljungberg, Johanna K., Nguyen, Tam T. K., Zamoshnikova, Alina, Kummari, Lalith K., Wyer, Orry J. K., Irvine, Katharine M., Melo-Bolívar, Javier, Gross, Annette, Brown, Darren, Mak, Jeffrey Y. W., Fairlie, David P., Hansford, Karl A., Cooper, Matthew A., Giri, Rabina, Schreiber, Veronika, Joseph, Shannon R., Simpson, Fiona, Barnett, Timothy C., Johansson, Jörgen, Dankers, Wendy, Harris, James, Wells, Timothy J., Kapetanovic, Ronan, Sweet, Matthew J. ... Blumenthal, Antje (2022). Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS Pathogens, 18 (1) e1010166, e1010166. doi: 10.1371/journal.ppat.1010166

Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis

Movva, Ramya, Murtaza, Nida, Giri, Rabina, Png, Chin Wen, Davies, Julie, Alabbas, Saleh, Oancea, Iulia, O'Cuiv, Páraic, Morrison, Mark, Begun, Jakob and Florin, Timothy H. (2022). Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis. Gastro Hep Advances, 1 (3), 359-374. doi: 10.1016/j.gastha.2021.12.008

Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis

Dignass, Axel U., Paridaens, Kristine, Al Awadhi, Sameer, Begun, Jakob, Cheon, Jae Hee, Fullarton, John R., Louis, Edouard, Magro, Fernando, Marquez, Juan Ricardo, Moschen, Alexander R., Narula, Neeraj, Rydzewska, Grazyna and Travis, Simon P. L. (2021). Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology, 57 (4), 1-8. doi: 10.1080/00365521.2021.2015801

Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero

Flanagan, Emma, Prentice, Ralley, Wright, Emily K., Gibson, Peter R., Ross, Alyson L., Begun, Jakob, Sparrow, Miles P., Goldberg, Rimma, Rosella, Ourania, Burns, Megan, Kiburg, Katerina V. and Bell, Sally J. (2021). Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Alimentary Pharmacology and Therapeutics, 55 (6), 700-704. doi: 10.1111/apt.16739

The psychosocial burden of inflammatory bowel disease in adolescents and young adults

Halloran, Jessica, McDermott, Brett, Ewais, Tatjana, Begun, Jakob, Karatela, Shamshad, D'Emden, Helen, Corias, Christian and Denny, Simon (2021). The psychosocial burden of inflammatory bowel disease in adolescents and young adults. Internal Medicine Journal, 51 (12) imj.15034, 2027-2033. doi: 10.1111/imj.15034

Facile synthesis of dendrimer like mesoporous silica nanoparticles to enhance targeted delivery of interleukin-22

Elshaer, Dana, Moniruzzaman, Md., Ong, Yi Theng, Qu, Zhi, Schreiber, Veronika, Begun, Jakob and Popat, Amirali (2021). Facile synthesis of dendrimer like mesoporous silica nanoparticles to enhance targeted delivery of interleukin-22. Biomaterials Science, 9 (22), 7402-7411. doi: 10.1039/d1bm01352a

Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement

Ilvemark, Johan F. K. F., Hansen, Tawnya, Goodsall, Thomas M., Seidelin, Jakob B., Al-Farhan, Heba, Allocca, Mariangela, Begun, Jakob, Bryant, Robert V., Carter, Dan, Christensen, Britt, Dubinsky, Marla C., Gecse, Krisztina B., Kucharzik, Torsten, Lu, Cathy, Maaser, Christian, Maconi, Giovanni, Nylund, Kim, Palmela, Carolina, Wilson, Stephanie R., Novak, Kerri and Wilkens, Rune (2021). Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement. Journal of Crohn's and Colitis, 16 (4), 554-580. doi: 10.1093/ecco-jcc/jjab173

Mindfulness based cognitive therapy for youth with inflammatory bowel disease and depression - Findings from a pilot randomised controlled trial

Ewais, T., Begun, J., Kenny, M., Hay, K., Houldin, Evan, Chuang, Kai-Hisang, Tefay, M. and Kisely, S. (2021). Mindfulness based cognitive therapy for youth with inflammatory bowel disease and depression - Findings from a pilot randomised controlled trial. Journal of Psychosomatic Research, 149 110594, 110594. doi: 10.1016/j.jpsychores.2021.110594

Expression of CD49f defines subsets of human regulatory T cells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity

Weerakoon, Harshi, Straube, Jasmin, Lineburg, Katie, Cooper, Leanne, Lane, Steven, Smith, Corey, Alabbas, Saleh, Begun, Jakob, Miles, John J., Hill, Michelle M. and Lepletier, Ailin (2021). Expression of CD49f defines subsets of human regulatory T cells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity. Clinical and Translational Immunology, 10 (9) e1334, e1334. doi: 10.1002/cti2.1334

Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas

De Gregorio, Michael, Lee, Tanya, Krishnaprasad, Krupa, Amos, Gregory, An, Yoon-Kyo, Bastian-Jordan, Matthew, Begun, Jakob, Borok, Nira, Brown, Dougal J. M., Cheung, Wa, Connor, Susan J., Gerstenmaier, Jan, Gilbert, Lauren E., Gilmore, Robert, Gu, Bonita, Kutaiba, Numan, Lee, Allan, Mahy, Gillian, Srinivasan, Ashish, Thin, Lena, Thompson, Alexander J., Welman, Christopher J., Yong, Eric X. Z., De Cruz, Peter, van Langenberg, Daniel, Sparrow, Miles P. and Ding, Nik S. (2021). Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas. Clinical Gastroenterology and Hepatology, 20 (6), 1306-1314. doi: 10.1016/j.cgh.2021.07.053

SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease

Prentice, Ralley E., Rentsch, Clarissa, Al‐Ani, Aysha H., Zhang, Eva, Johnson, Douglas, Halliday, John, Bryant, Robert, Begun, Jacob, Ward, Mark G., Lewindon, Peter J., Connor, Susan J., Ghaly, Simon and Christensen, Britt (2021). SARS‐CoV‐2 vaccination in patients with inflammatory bowel disease. GastroHep, 3 (4), 212-228. doi: 10.1002/ygh2.473

Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol

Gu, Bonita, De Gregorio, Michael, Pipicella, Joseph Louis, Vande Casteele, Niels, Andrews, Jane M., Begun, Jakob, Connell, William, D'Souza, Basil, Gholamrezaei, Ali, Hart, Ailsa, Liew, Danny, Radford-Smith, Graham, Rimola, Jordi, Sutherland, Tom, Toong, Catherine, Woods, Rodney, Wu, Yang, Xuan, Wei, Williams, Astrid-Jane, Ng, Watson, Ding, Nik Sheng and Connor, Susan (2021). Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ open, 11 (7) 043921. doi: 10.1136/bmjopen-2020-043921

IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease

Henden, Andrea S., Koyama, Motoko, Robb, Renee J., Forero, Adriana, Kuns, Rachel D., Chang, Karshing, Ensbey, Kathleen S., Varelias, Antiopi, Kazakoff, Stephen H., Waddell, Nicole, Clouston, Andrew D., Giri, Rabina, Begun, Jakob, Blazar, Bruce R., Degli-Esposti, Mariapia A., Kotenko, Sergei V., Lane, Steven W., Bowerman, Kate L., Savan, Ram, Hugenholtz, Philip, Gartlan, Kate H. and Hill, Geoffrey R. (2021). IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease. Blood, 138 (8), 722-737. doi: 10.1182/blood.2020006375

pH – responsive colloidal carriers assembled from β-lactoglobulin and epsilon poly-l-lysine for oral drug delivery

Pujara, Naisarg, Giri, Rabina, Yau Wong, Kuan, Qu, Zhi, Rewatkar, Prarthana, Moniruzzaman, Md., Begun, Jakob, Ross, Benjamin P., McGuckin, Michael and Popat, Amirali (2021). pH – responsive colloidal carriers assembled from β-lactoglobulin and epsilon poly-l-lysine for oral drug delivery. Journal of Colloid and Interface Science, 589, 45-55. doi: 10.1016/j.jcis.2020.12.054

Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease

Goodsall, Thomas M., Jairath, Vipul, Feagan, Brian G., Parker, Claire E., Nguyen, Tran M., Guizzetti, Leonardo, Asthana, Anil K., Begun, Jakob, Christensen, Britt, Friedman, Antony B., Kucharzik, Torsten, Lee, Andrew, Lewindon, Peter J., Maaser, Christian, Novak, Kerri L., Rimola, Jordi, Taylor, Kirstin M., Taylor, Stuart A., White, Lauren S., Wilkens, Rune, Wilson, Stephanie R., Wright, Emily K., Bryant, Robert V. and Ma, Christopher (2021). Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease. Alimentary Pharmacology and Therapeutics, 53 (8), 873-886. doi: 10.1111/apt.16288

Adhesion to E-selectin primes macrophages for activation through AKT and mTOR

Davies, Julie M., Radford, Kristen J., Begun, Jakob, Levesque, Jean-Pierre and Winkler, Ingrid G. (2021). Adhesion to E-selectin primes macrophages for activation through AKT and mTOR. Immunology and Cell Biology, 99 (6) imcb.12447, 622-639. doi: 10.1111/imcb.12447

A nucleotide analog prevents colitis associated cancer via Β-catenin independently of inflammation and autophagy

Sheng, Yong Hua, Giri, Rabina, Davies, Julie, Schreiber, Veronika, Alabbas, Saleh, Movva, Ramya, He, Yaowu, Wu, Andy, Hooper, John, McWhinney, Brett, Oancea, Iulia, Kijanka, Gregor, Hasnain, Sumaira, Lucke, Andrew J., Fairlie, David P., McGuckin, Michael A., Florin, Timothy H. and Begun, Jakob (2021). A nucleotide analog prevents colitis associated cancer via Β-catenin independently of inflammation and autophagy. Cellular and Molecular Gastroenterology and Hepatology, 11 (1), 33-53. doi: 10.1016/j.jcmgh.2020.05.012

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

Klionsky, Daniel J., Abdel-Aziz, Amal Kamal, Abdelfatah, Sara, Abdellatif, Mahmoud, Abdoli, Asghar, Abel, Steffen, Abeliovich, Hagai, Abildgaard, Marie H., Abudu, Yakubu Princely, Acevedo-Arozena, Abraham, Adamopoulos, Iannis E., Adeli, Khosrow, Adolph, Timon E., Adornetto, Annagrazia, Aflaki, Elma, Agam, Galila, Agarwal, Anupam, Aggarwal, Bharat B., Agnello, Maria, Agostinis, Patrizia, Agrewala, Javed N., Agrotis, Alexander, Aguilar, Patricia V., Ahmad, S. Tariq, Ahmed, Zubair M., Ahumada-Castro, Ulises, Aits, Sonja, Aizawa, Shu, Akkoc, Yunus ... Tong, Chun-Kit (2021). Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy, 17 (1), 1-382. doi: 10.1080/15548627.2020.1797280

Gut microbiota shape the inflammatory response in mice with an epithelial defect

Wang, Ran, Moniruzzaman, Md, Wong, Kuan Yau, Wiid, Percival, Harding, Alexa, Giri, Rabina, Tong, Wendy Hui, Creagh, Jackie, Begun, Jakob, McGuckin, Michael A. and Hasnain, Sumaira Z. (2021). Gut microbiota shape the inflammatory response in mice with an epithelial defect. Gut microbes, 13 (1), 1-18. doi: 10.1080/19490976.2021.1887720

IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread

Roney, Md Saiful Islam, Lanagan, Catharine, Sheng, Yong Hua, Lawler, Karen, Schmidt, Christopher, Nguyen, Nam‐Trung, Begun, Jakob and Kijanka, Gregor Stefan (2021). IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread. Clinical and Translational Immunology, 10 (9) e1330, e1330. doi: 10.1002/cti2.1330

Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease

Krishnaprasad, Krupa, Walsh, Alissa, Begun, Jakob, Bell, Sally, Carter, David, Grafton, Rachel, Sechi, Alexandra, Sewell, Karen, McMahon, Anna, Connor, Susan, Radford-Smith, Graham and Andrews, Jane M. (2020). Crohn’s Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 55 (12), 1419-1426. doi: 10.1080/00365521.2020.1839960

Mindfulness-based cognitive therapy experiences in youth with inflammatory bowel disease and depression: findings from a mixed methods qualitative study

Ewais, Tatjana, Begun, Jake, Kenny, Maura, Headey, Alan, Tefay, Merilyn and Kisely, Steve (2020). Mindfulness-based cognitive therapy experiences in youth with inflammatory bowel disease and depression: findings from a mixed methods qualitative study. BMJ Open, 10 (11) e041140, e041140. doi: 10.1136/bmjopen-2020-041140

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study

Haifer, Craig, Srinivasan, Ashish, An, Yoon‐Kyo, Picardo, Sherman, Langenberg, Daniel, Menon, Shankar, Begun, Jakob, Ghaly, Simon and Thin, Lena (2020). Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Medical Journal of Australia, 214 (3) mja2.50824, 128-133. doi: 10.5694/mja2.50824

One‐pot synthesis of pH‐responsive eudragit‐mesoporous silica nanocomposites enable colonic delivery of glucocorticoids for the treatment of inflammatory bowel disease

Qu, Zhi, Wong, Kuan Yau, Moniruzzaman, Md., Begun, Jakob, Santos, Hélder A, Hasnain, Sumaira Z., Kumeria, Tushar, McGuckin, Michael A. and Popat, Amirali (2020). One‐pot synthesis of pH‐responsive eudragit‐mesoporous silica nanocomposites enable colonic delivery of glucocorticoids for the treatment of inflammatory bowel disease. Advanced Therapeutics, 4 (2) 2000165, 2000165. doi: 10.1002/adtp.202000165

Monitoring inflammatory bowel disease in pregnancy using gastrointestinal ultrasonography

Flanagan, Emma, Wright, Emily K., Begun, Jakob, Bryant, Robert V., An, Yoon-Kyo, Ross, Alyson L., Kiburg, Katerina V. and Bell, Sally J. (2020). Monitoring inflammatory bowel disease in pregnancy using gastrointestinal ultrasonography. Journal of Crohn's and Colitis, 14 (10), 1405-1412. doi: 10.1093/ecco-jcc/jjaa082

Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

Reddy Pulusu, Samba Siva, Srinivasan, Ashish, Krishnaprasad, Krupa, Cheng, Daniel, Begun, Jakob, Keung, Charlotte, Van Langenberg, Daniel, Thin, Lena, Mogilevski, Tamara, de Cruz, Peter, Radford-Smith, Graham, Flanagan, Emma, Bell, Sally, Kashkooli, Soleiman, Sparrow, Miles, Ghaly, Simon, Bampton, Peter, Sawyer, Elise, Connor, Susan, Rizvi, Quart-Ul-Ain, Andrews, Jane M., Mahy, Gillian, Chivers, Paola, Travis, Simon and CraigLawrance, Ian (2020). Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World Journal of Gastroenterology, 26 (30), 4428-4441. doi: 10.3748/WJG.V26.I30.4428

Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty

Aysha, Al-Ani, Rentsch, Clarissa, Prentice, Ralley, Johnson, Doug, Bryant, Robert V., Ward, Mark G., Costello, Samuel P., Lewindon, Peter, Ghaly, Simon, Connor, Susan J., Begun, Jakob and Christensen, Britt (2020). Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. Internal Medicine Journal, 50 (7), 798-804. doi: 10.1111/imj.14889

The future of faecal microbiota transplantation in gastrointestinal illness

Reed, Hayley and Begun, Jakob (2020). The future of faecal microbiota transplantation in gastrointestinal illness. Microbiology Australia, 41 (2), 70-74. doi: 10.1071/ma20027

Aeromedical retrievals for gastrointestinal disorders in rural and remote Australia: the need for improved access to specialist advice

Gardiner, Fergus W, Bishop, Lara, McMahon, Kathryn, Nwose, Ezekiel U, Connor, Susan, Begun, Jakob and Andrews, Jane M. (2020). Aeromedical retrievals for gastrointestinal disorders in rural and remote Australia: the need for improved access to specialist advice. Internal medicine journal, 50 (5), 619-623. doi: 10.1111/imj.14822

Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice

Haifer, Craig, Kelly, Colleen R., Paramsothy, Sudarshan, Andresen, David, Papanicolas, Lito E., McKew, Genevieve L., Borody, Thomas J., Kamm, Michael, Costello, Samuel P., Andrews, Jane M., Begun, Jakob, Chan, Hiu Tat, Connor, Susan, Ghaly, Simon, Johnson, Paul D. R., Lemberg, Daniel A., Paramsothy, Ramesh, Redmond, Andrew, Sheorey, Harsha, van der Poorten, David and Leong, Rupert W. (2020). Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. Gut, 69 (5) 320260, 801-810. doi: 10.1136/gutjnl-2019-320260

Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure

Flanagan, Emma, Gibson, Peter R., Wright, Emily K., Moore, Gregory T., Sparrow, Miles P., Connell, William, Kamm, Michael A., Begun, Jakob, Christensen, Britt, De Cruz, Peter, Shelton, Edward, Dowling, Damian, Andrews, Jane M., Brown, Steven J., Niewiadomski, Olga, Ward, Mark G., Rosella, Ourania, Rosella, Gennaro, Kiburg, Katerina V., Ross, Alyson L. and Bell, Sally J. (2020). Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Alimentary Pharmacology and Therapeutics, 52 (10), 1551-1562. doi: 10.1111/apt.16102

MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota

Koyama, Motoko, Mukhopadhyay, Pamela, Schuster, Iona S., Henden, Andrea S., Hülsdünker, Jan, Varelias, Antiopi, Vetizou, Marie, Kuns, Rachel D., Robb, Renee J., Zhang, Ping, Blazar, Bruce B., Thomas, Ranjeny, Begun, Jakob, Waddell, Nicola, Trinchieri, Giorgio, Zeiser, Robert, Clouston, Andrew D., Degli-Esposti, Mariapia A. and Hill, Geoffrey R. (2019). MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota. Immunity, 51 (5), 885-898. doi: 10.1016/j.immuni.2019.08.011

Malnutrition and quality of life among adult inflammatory bowel disease patients

Pulley, Jessica, Todd, Alwyn, Flatley, Christopher and Begun, Jakob (2019). Malnutrition and quality of life among adult inflammatory bowel disease patients. JGH Open, 4 (3), 454-460. doi: 10.1002/jgh3.12278

Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta‐analysis

An, Yoon‐Kyo, Prince, David, Gardiner, Fergus, Neeman, Teresa, Linedale, Ecushla C., Andrews, Jane M., Connor, Susan and Begun, Jakob (2019). Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta‐analysis. Medical Journal of Australia, 211 (10) mja2.50384, 461-467. doi: 10.5694/mja2.50384

Gastrointestinal ultrasound in inflammatory bowel disease care: patient perceptions and impact on disease‐related knowledge

Rajagopalan, Arvind, Sathananthan, Dharshan, An, Yoon‐Kyo, Van De Ven, Lucinda, Martin, Serena, Fon, James, Costello, Samuel P, Begun, Jakob and Bryant, Robert V (2019). Gastrointestinal ultrasound in inflammatory bowel disease care: patient perceptions and impact on disease‐related knowledge. JGH Open, 4 (2) jgh3.12268, 267-272. doi: 10.1002/jgh3.12268

Distinct tissue-specific roles for the disease-associated autophagy genes ATG16L2 and ATG16L1

Khor, Bernard, Conway, Kara L., Omar, Abdifatah S., Biton, Moshe, Haber, Adam L., Rogel, Noga, Baxt, Leigh A., Begun, Jakob, Kuballa, Petric, Gagnon, John D., Lassen, Kara G., Regev, Aviv and Xavier, Ramnik J. (2019). Distinct tissue-specific roles for the disease-associated autophagy genes ATG16L2 and ATG16L1. The Journal of Immunology, 203 (7), ji1800419-1829. doi: 10.4049/jimmunol.1800419

MUC13 promotes the development of colitis-associated colorectal tumors via β-catenin activity

Sheng, Yong Hua, Wong, Kuan Yau, Seim, Inge, Wang, Ran, He, Yaowu, Wu, Andy, Patrick, Maya, Lourie, Rohan, Schreiber, Veronika, Giri, Rabina, Ng, Choa Ping, Popat, Amirali, Hooper, John, Kijanka, Gregor, Florin, Timothy H., Begun, Jakob, Radford, Kristen J., Hasnain, Sumaira and McGuckin, Michael A. (2019). MUC13 promotes the development of colitis-associated colorectal tumors via β-catenin activity. Oncogene, 38 (48), 7294-7310. doi: 10.1038/s41388-019-0951-y

Mindfulness based cognitive therapy experiences in youth with inflammatory bowel disease and depression: protocol for a mixed methods qualitative study

Ewais, Tatjana, Begun, Jake, Kenny, Maura, Headey, Alan and Kisely, Steve (2019). Mindfulness based cognitive therapy experiences in youth with inflammatory bowel disease and depression: protocol for a mixed methods qualitative study. JMIR Research Protocols, 8 (7) e14432, e14432. doi: 10.2196/14432

Immune responses to the microbiome tune MHC class II antigen presentation by the intestinal epithelium to control gut pathology

Koyama, Motoko, Mukhopadhyay, Pamela, Schuster, Iona S, Henden, Andrea S, Hülsdünker, Jan, Varelias, Antiopi, Vetizou, Marie, Kuns, Rachel D, Robb, Renee J, Zhang, Ping, Blazar, Bruce R., Thomas, Ranjeny, Begun, Jakob, Waddell, Nicola, Trinchieri, Giorgio, Zeiser, Robert, Clouston, Andrew D, Degli-Esposti, Mariapia A and Hill, Geoffrey R. (2019). Immune responses to the microbiome tune MHC class II antigen presentation by the intestinal epithelium to control gut pathology. The Journal of Immunology, 202 (1_Supplement), 69.38-69.38. doi: 10.4049/jimmunol.202.supp.69.38

Clinical decision support improves quality of care in patients with ulcerative colitis

Jackson, Belinda, Begun, Jake, Gray, Kathleen, Churilov, Leonid, Liew, Danny, Knowles, Simon and De Cruz, Peter (2019). Clinical decision support improves quality of care in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 49 (8), 1040-1051. doi: 10.1111/apt.15209

Interleukin-22: friend or foe?

Hasnain, Sumaira Z. and Begun, Jakob (2019). Interleukin-22: friend or foe?. Immunology and Cell Biology, 97 (4), 355-357. doi: 10.1111/imcb.12249

Protocol for a pilot randomised controlled trial of mindfulness-based cognitive therapy in youth with inflammatory bowel disease and depression

Ewais, Tatjana, Begun, Jake, Kenny, Maura, Chuang, Kai-Hsiang, Barclay, Johanna, Hay, Karen and Kisely, Steve (2019). Protocol for a pilot randomised controlled trial of mindfulness-based cognitive therapy in youth with inflammatory bowel disease and depression. BMJ Open, 9 (4) e025568, e025568. doi: 10.1136/bmjopen-2018-025568

A systematic review and meta-analysis of mindfulness based interventions and yoga in inflammatory bowel disease

Ewais, Tatjana, Begun, Jake, Kenny, Maura, Rickett, Kirsty, Hay, Karen, Ajilchi, Bita and Kisely, Steve (2019). A systematic review and meta-analysis of mindfulness based interventions and yoga in inflammatory bowel disease. Journal of Psychosomatic Research, 116, 44-53. doi: 10.1016/j.jpsychores.2018.11.010

Letter: vedolizumab drug concentrations in neonates following intrauterine exposure

Flanagan, Emma, Gibson, Peter R., Begun, Jakob, Ghaly, Simon, Garg, Mayur, Andrews, Jane M., Rosella, Ourania, Rosella, Gennaro and Bell, Sally J. (2018). Letter: vedolizumab drug concentrations in neonates following intrauterine exposure. Alimentary Pharmacology and Therapeutics, 48 (11-12), 1328-1330. doi: 10.1111/apt.15027

Personalizing inflammatory bowel disease treatment symposium: Foreward

Begun, Jakob (2018). Personalizing inflammatory bowel disease treatment symposium: Foreward. Journal of Gastroenterology and Hepatology, 33 (S3), 3-3. doi: 10.1111/jgh.14414

Enterococcus faecalis AHG0090 is a genetically tractable bacterium and produces a secreted peptidic bioactive that suppresses nuclear factor Kappa B activation in human gut epithelial cells

Ó Cuív, Páraic, Giri, Rabina, Hoedt, Emily C., McGuckin, Michael A., Begun, Jakob and Morrison, Mark (2018). Enterococcus faecalis AHG0090 is a genetically tractable bacterium and produces a secreted peptidic bioactive that suppresses nuclear factor Kappa B activation in human gut epithelial cells. Frontiers in Immunology, 9 (April) 790, 790. doi: 10.3389/fimmu.2018.00790

The role of IL-22 in the resolution of sterile and nonsterile inflammation

Alabbas, Saleh Y, Begun, Jakob, Florin, Timothy H and Oancea, Iulia (2018). The role of IL-22 in the resolution of sterile and nonsterile inflammation. Clinical and Translational Immunology, 7 (4) e1017, e1017. doi: 10.1002/cti2.1017

Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application

Bryant, Robert Venning, Friedman, Antony, Wright, Emily Kate, Taylor, Kirstin, Begun, Jakob, Maconi, Giovanni, Maaser, Christian, Novak, Kerri L., Kucharzik, Torsten, Atkinson, Nathan S. S., Asthana, Anil and Gibson, Peter R. (2018). Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut, 67 (5), 973-985. doi: 10.1136/gutjnl-2017-315655

Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases

Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., Begun, J., Bryant, R., Chan, W., Corte, C., Ghaly, S., Lemberg, D. A., Kariyawasam, V., Lewindon, P., Martin, J., Mountifield, R., Radford-Smith, G., Slobodian, P., Sparrow, M., Toong, C., van Langenberg, D., Ward, M. G. and Leong, R. W. (2017). Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics, 46 (11-12), 1037-1053. doi: 10.1111/apt.14368

Colonic thioguanine pro-drug: investigation of microbiome and novel host metabolism

Florin, Timothy, Movva, Ramya, Begun, Jakob, Duley, John, Oancea, Iulia and O Cuiv, Paraic (2017). Colonic thioguanine pro-drug: investigation of microbiome and novel host metabolism. Gut Microbes, 9 (2), 1-4. doi: 10.1080/19490976.2017.1387343

The gut bacterium and pathobiont Bacteroides vulgatus activates NF-κB in a human gut epithelial cell line in a strain and growth phase dependent manner

Cuív, Páraic Ó., de Wouters, Tomas, Giri, Rabina, Mondot, Stanislas, Smith, Wendy J., Blottière, Hervé M., Begun, Jakob and Morrison, Mark (2017). The gut bacterium and pathobiont Bacteroides vulgatus activates NF-κB in a human gut epithelial cell line in a strain and growth phase dependent manner. Anaerobe, 47, 209-217. doi: 10.1016/j.anaerobe.2017.06.002

Cancer therapeutics with epigallocatechin-3-gallate encapsulated in biopolymeric nanoparticles

Tyagi, Nisha, De, Ranjit, Begun, Jakob and Popat, Amirali (2017). Cancer therapeutics with epigallocatechin-3-gallate encapsulated in biopolymeric nanoparticles. International Journal of Pharmaceutics, 518 (1-2), 220-227. doi: 10.1016/j.ijpharm.2016.12.030

The role of barrier function, autophagy, and cytokines in maintaining intestinal homeostasis

Elshaer, Dana and Begun, Jakob (2016). The role of barrier function, autophagy, and cytokines in maintaining intestinal homeostasis. Seminars in Cell and Developmental Biology, 61, 51-59. doi: 10.1016/j.semcdb.2016.08.018

Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism

Oancea, I., Movva, R., Das, I., Aguirre de Carcer, D., Schreiber, V., Yang, Y., Purdon, A., Harrington, B., Proctor, M., Wang, R., Sheng, Y., Lobb, M., Lourie, R., Cuiv, P.O., Duley, J.A., Begun, J. and Florin, T.H.J. (2016). Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism. Gut, 66 (1), 59-69. doi: 10.1136/gutjnl-2015-310874

High fat diets induce colonic epithelial cell stress and inflammation that is reversed by IL-22

Gulhane, Max, Murray, Lydia, Lourie, Rohan, Tong, Hui, Sheng, Yong H., Wang, Ran, Kang, Alicia, Schreiber, Veronika, Wong, Kuan Yau, Magor, Graham, Denman, Stuart, Begun, Jakob, Florin, Timothy H., Perkins, Andrew, Cuiv, Paraic O., McGuckin, Michael A. and Hasnain, Sumaira Z. (2016). High fat diets induce colonic epithelial cell stress and inflammation that is reversed by IL-22. Scientific Reports, 6 (1) 28990, 28990. doi: 10.1038/srep28990

Genetic coding variant in GPR65 alters lysosomal pH and links lysosomal dysfunction with colitis risk

Lassen, Kara G., McKenzie, Craig I., Mari, Muriel, Murano, Tatsuro, Begun, Jakob, Baxt, Leigh A., Goel, Gautam, Villablanca, Eduardo J., Kuo, Szu-Yu, Huang, Hailiang, Macia, Laurence, Bhan, Atul K., Batten, Marcel, Daly, Mark J., Reggiori, Fulvio, Mackay, Charles R. and Xavier, Ramnik J. (2016). Genetic coding variant in GPR65 alters lysosomal pH and links lysosomal dysfunction with colitis risk. Immunity, 44 (6), 1392-1405. doi: 10.1016/j.immuni.2016.05.007

Towards an integrated understanding of the therapeutic utility of exclusive enteral nutrition in the treatment of Crohn's disease

O Cuiv, Paraic, Begun, Jake, Keely, Simon, Lewindon, Peter and Morrison, Mark (2016). Towards an integrated understanding of the therapeutic utility of exclusive enteral nutrition in the treatment of Crohn's disease. Food and Function, 7 (4), 1741-1751. doi: 10.1039/C5FO01196E

Integrated genomics of crohn's disease risk variant identifies a role for CLEC12A in antibacterial autophagy

Begun, Jakob, Lassen, Kara G., Jijon, Humberto B., Baxt, Leigh A., Goel, Gautam, Heath, Robert J., Ng, Aylwin, Tam, Jenny M., Kuo, Szu-Yu, Villablanca, Eduardo J., Fagbami, Lola, Oosting, Marije, Kumar, Vinod, Schenone, Monica, Carr, Steven A., Joosten, Leo A. B., Vyas, Jatin M., Daly, Mark J., Netea, Mihai G., Brown, Gordon D., Wijmenga, Cisca and Xavier, Ramnik J. (2015). Integrated genomics of crohn's disease risk variant identifies a role for CLEC12A in antibacterial autophagy. Cell Reports, 11 (12), 1905-1918. doi: 10.1016/j.celrep.2015.05.045

Enteroliths in a Kock continent ileostomy: case report and review of the literature

Moattar, Hadi, Begun, Jakob and Florin, Timothy (2015). Enteroliths in a Kock continent ileostomy: case report and review of the literature. Endoscopy, 47 (S 01), E200-E201. doi: 10.1055/s-0034-1391302

IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans

de Luca, Antonella, Smeekens, Sanne P., Casagrande, Andrea, Iannitti, Rossana, Conway, Kara L., Gresnigt, Mark. S., Begun, Jakob, Plantinga, Theo S., Joosten, Leo A. B., van der Meer, Jos W. M., Chamilos, Georgios, Netea, Mihai G., Xavier, Ramnik J., Dinarello, Charles A., Romani, Luigina and van de Veerdonk, Frank L. (2014). IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proceedings of the National Academy of Sciences of the United States of America, 111 (9), 3526-3531. doi: 10.1073/pnas.1322831111

Autophagy at the crossroads of metabolism and cellular defense

Begun, Jakob and Xavier, Ramnik J. (2013). Autophagy at the crossroads of metabolism and cellular defense. Current Opinion in Gastroenterology, 29 (6), 588-596. doi: 10.1097/MOG.0b013e328365d34d

Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis

Beaudoin, Melissa, Goyette, Philippe, Boucher, Gabrielle, Lo, Ken Sin, Rivas, Manuel A., Stevens, Christine, Alikashani, Azadeh, Ladouceur, Martin, Ellinghaus, David, Torkvist, Leif, Goel, Gautam, Lagace, Caroline, Annese, Vito, Bitton, Alain, Begun, Jakob, Brant, Steve R., Bresso, Francesca, Cho, Judy H., Duerr, Richard H., Halfvarson, Jonas, McGovern, Dermot P. B., Radford-Smith, Graham, Schreiber, Stefan, Schumm, Philip L., Sharma, Yashoda, Silverberg, Mark S., Weersma, Rinse K., D'Amato, Mauro, Vermeire, Severine ... Rioux, John D. (2013). Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genetics, 9 (9) e1003723, e1003723.1-e1003723.11. doi: 10.1371/journal.pgen.1003723

ATG16L1 T300A dependent differential gene expression identifies genes required for anti-bacterial autophagy : P-227 YI

Begun, Jakob, Ng, Aylwin and Xavier, Ramnik (2012). ATG16L1 T300A dependent differential gene expression identifies genes required for anti-bacterial autophagy : P-227 YI. Inflammatory Bowel Diseases, 18, S103. doi: 10.1097/00054725-201212001-00260

The LRR and RING domain protein LRSAM1 is an E3 ligase crucial for ubiquitin-dependent autophagy of intracellular salmonella typhimurium

Huett, Alan, Heath, Robert J., Begun, Jakob, Sassi, Slim O., Baxt, Leigh A., Vyas, Jatin M., Goldberg, Marcia B. and Xavier, Ramnik J. (2012). The LRR and RING domain protein LRSAM1 is an E3 ligase crucial for ubiquitin-dependent autophagy of intracellular salmonella typhimurium. Cell Host and Microbe, 12 (6), 778-790. doi: 10.1016/j.chom.2012.10.019

DAF-16-dependent suppression of immunity during reproduction in Caenorhabditis elegans

Miyata, Sachiko, Begun, Jakob, Troemel, Emily R. and Ausubel, Frederick M. (2008). DAF-16-dependent suppression of immunity during reproduction in Caenorhabditis elegans. Genetics, 178 (2), 903-918. doi: 10.1534/genetics.107.083923

Staphylococcal biofilm exopolysaccharide protects against Caenorhabditis elegans immune defenses

Begun, Jakob, Gaiani, Jessica M., Rohde, Holger, Mack, Dietrich, Calderwood, Stephen B., Ausubel, Frederick M. and Sifri, Costi D. (2007). Staphylococcal biofilm exopolysaccharide protects against Caenorhabditis elegans immune defenses. PLoS Pathogens, 3 (4), 526-540. doi: 10.1371/journal.ppat.0030057

Staphylococcus aureus virulence factors identified by using a high-throughput Caenorhabditis elegans-killing model

Begun, Jakob, Sifri, Costi D., Goldman, Samuel, Calderwood, Stephen B. and Ausubel, Frederick M. (2005). Staphylococcus aureus virulence factors identified by using a high-throughput Caenorhabditis elegans-killing model. Infection and Immunity, 73 (2), 872-877. doi: 10.1128/IAI.73.2.872-877.2005

The worm has turned - Microbial virulence modeled in Caenorhabditis elegans

Sifri, CD, Begun, J and Ausubel, FM (2005). The worm has turned - Microbial virulence modeled in Caenorhabditis elegans. Trends in Microbiology, 13 (3), 119-127. doi: 10.1016/j.tim.2005.01.003

Bacterial Resistance of daf-2 Mutants [2] (multiple letters)

Bolm, Maike, Chhatwal, Gursharan S., Jansen, Wouter T. M., Ausubel, Frederick M., Begun, Jakob, Kim, Dennis H., Moy, Terence, Ruvkun, Gary, Calderwood, Stephen B., Sifri, Costi D. and Garsin, Danielle A. (2004). Bacterial Resistance of daf-2 Mutants [2] (multiple letters). Science, 303 (5666)

Long-lived C. elegans daf-2 Mutants are resistant to bacterial pathogens

Garsin, DA, Villanueva, JM, Begun, J, Kim, DH, Sifri, CD, Calderwood, SB, Ruvkun, G and Ausubel, FM (2003). Long-lived C. elegans daf-2 Mutants are resistant to bacterial pathogens. Science, 300 (5627), 1921-1921. doi: 10.1126/science.1080147

Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis

Sifri, Costi D., Begun, Jakob, Ausubel, Frederick M. and Calderwood, Stephen B. (2003). Caenorhabditis elegans as a model host for Staphylococcus aureus pathogenesis. Infection and Immunity, 71 (4), 2208-2217. doi: 10.1128/IAI.71.4.2208-2217.2003

Crystal structure of an Xrcc4-DNA ligase IV complex

Sibanda, Bancinyane L., Critchlow, Susan E., Begun, Jake, Pei, Xue Y., Jackson, Stephen P., Blundell, Tom L. and Pellegrini, Luca (2001). Crystal structure of an Xrcc4-DNA ligase IV complex. Nature Structural Biology, 8 (12), 1015-1019. doi: 10.1038/nsb725

Getting the adrenaline going: Crystal structure of the adrenaline-synthesizing enzyme PNMT

Martin, J. L., Begun, J., McLeish, M. J., Caine, J. M. and Grunewald, G. L. (2001). Getting the adrenaline going: Crystal structure of the adrenaline-synthesizing enzyme PNMT. Structure, 9 (10), 977-985. doi: 10.1016/S0969-2126(01)00662-1

Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease

Martin, J. L., Begun, J., Schindeler, A., Wickramasinghe, W. A., Alewood, D., Alewood, P. F., Bergman, D. A., Brinkworth, R. I., Abbenante, G., March, D. R., Reid, R. C., Fairlie, D. P. and Armstrong, Richard A. (1999). Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Biochemistry, 38 (25), 7978-7988. doi: 10.1021/bi990174x

Substrate-based cyclic peptidomimetics of Phe-Ile-Val that inhibit HIV-1 protease using a novel enzyme-binding mode

March, D. R., Abbenante, G., Bergman, D. A., Brinkworth, R. I., Wickramasinghe, W., Begun, J., Martin, J. L. and Fairlie, D. P. (1996). Substrate-based cyclic peptidomimetics of Phe-Ile-Val that inhibit HIV-1 protease using a novel enzyme-binding mode. Journal of The American Chemical Society, 118 (14), 3375-3379. doi: 10.1021/ja953790z

Australian consensus on ustekinumab in Crohn's disease

Begun, J., An, Y-K, Bryant, R., Christensen, B., Leong, R., Studd, C. and Thin, L. (2023). Australian consensus on ustekinumab in Crohn's disease. HOBOKEN: WILEY.

Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis

Gilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugopal, K., Han, S., Bryant, R., Corte, C., Ding, J. N., An, Y-K and Begun, J. (2023). Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis. HOBOKEN: WILEY.

Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDC

Fernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Moore, G., Gazelakis, K., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Judge, C., Ngoi, B., Lynch, K., Begun, J. and An, Y-K (2023). Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDC. HOBOKEN: WILEY.

Delayed flexible sigmoidoscopy remains a challenge in tertiary care of acute severe colitis

Rice, K., Fernandes, R., Hendy, P., Khoo, E., Walker, N., Howlett, M., An, Y-K and Begun, J. (2023). Delayed flexible sigmoidoscopy remains a challenge in tertiary care of acute severe colitis. HOBOKEN: WILEY.

Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience

Gilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. HOBOKEN: WILEY.

Fistulizing Crohn's disease in a large real-world cohort: Crohn's Colitis Cure data insights program

Mcnamara, J., Wilson, W., Pipicella, J., Ghaly, S., Gearry, R., Forbes, A., Begun, J., Ng, W., Lynch, K., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Britt, L., Verdon, C., Andrews, J. and Connor, S. (2023). Fistulizing Crohn's disease in a large real-world cohort: Crohn's Colitis Cure data insights program. HOBOKEN: WILEY.

From enemies to friends: Exploring the capacity of novel compounds secreted by "pathobiont" gut bacteria to attenuate inflammation in inflammatory bowel disease

Reed, H., Sehgal, A., Morrison, M. and Begun, J. (2023). From enemies to friends: Exploring the capacity of novel compounds secreted by "pathobiont" gut bacteria to attenuate inflammation in inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Impact of disease duration on predicting response to vedolizumab in patients with ulcerative colitis from the Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS)

Choi, R. C-H, Pudipeddi, A., Lin, H., Paramsothy, S., Ghaly, S., Begun, J., Kariyawasam, V., Yau, Y., Fung, C. and Leong, R. (2023). Impact of disease duration on predicting response to vedolizumab in patients with ulcerative colitis from the Vedolizumab Immunomodulator Enforced Withdrawal Study (VIEWS). HOBOKEN: WILEY.

Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease

Tan, W. L., Barr, E., Pham, H., Fernandes, R., Khoo, E., An, Y-K and Begun, J. (2023). Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease. HOBOKEN: WILEY.

Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCC

Fernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Gazelakis, K., Moore, G., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Lynch, K., Ngoi, B., Judge, C., Kim, D. H., Kim, H. S., Lee, H. S., Kim, K. O., Lee, Y. J., Kim, S-J, Lee, J., Song, E. M., Park, S. H. ... An, Y-K (2023). Patients from East Asia with acute severe ulcerative colitis have worse endoscopic severity but are more responsive to intravenous steroids than patients from Australasia: Preliminary results of the APAC-ASUC study in collaboration with the ANZIBDC and AOCC. HOBOKEN: WILEY.

Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study

Etchegaray, A., Fernandes, R., Anandan, A. Shanmuga, Selvanathan, P., Malloy, R., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study. HOBOKEN: WILEY.

Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound

Fernandes, R., Harris, H., Khoo, E., Gilmore, R., Howlett, M., Walker, N., Hendy, P., Begun, J. and An, Y-K (2023). Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound. HOBOKEN: WILEY.

The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portal

Mcnamara, J., Pipicella, J., Ghaly, S., Gearry, R., Forbes, A., Begun, J., Wark, G., Lynch, K., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Brett, L., Verdon, C., Andrews, J. and Connor, S. (2023). The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portal. HOBOKEN: WILEY.

Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report

Etchegaray, A., Gilmore, R., An, Y-K and Begun, J. (2023). Upadacitinib and vedolizumab combination therapy for recalcitrant, steroid-refractory Crohn's disease: A case report. HOBOKEN: WILEY.

Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience

Tan, W. L., Gilmore, R., Huang, A., Fernandes, R., An, Y-K and Begun, J. (2023). Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience. HOBOKEN: WILEY.

Upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn's disease irrespective of previous failure to respond to biologics or conventional therapies

Begun, J., Feagan, B., Horst, S., Dryden, G., Lindsay, J., Ferrante, M., Dubcenco, E., Lacerda, A., Ford, S., Anyanwu, S., Zhou, Q., Liu, J., Chen, M. and Schreiber, S. (2023). Upadacitinib improves endoscopic outcomes in patients with moderate to severely active Crohn's disease irrespective of previous failure to respond to biologics or conventional therapies. HOBOKEN: WILEY.

Variation of outcomes in inflammatory bowel disease at 10 Australian and New Zealand centers: Crohn's Colitis Cure data insights program

Mcnamara, J., Ghaly, S., Pipicella, J., Wilson, W., Goodfellow, T., Cheema, M., Lynch, K., Williams, A., Begun, J., Gearry, R., Kim, A., Haifer, C., Forbes, A., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Andrews, J. and Connor, S. (2023). Variation of outcomes in inflammatory bowel disease at 10 Australian and New Zealand centers: Crohn's Colitis Cure data insights program. HOBOKEN: WILEY.

Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study

Anandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. HOBOKEN: WILEY.

Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trial

Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y-K, Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D., Chan, W., Mourad, F. and Leong, R. (2023). Withdrawal vs continuation of thiopurine in vedolizumab-treated patients with ulcerative colitis (VIEWS): A multicenter randomized controlled trial. HOBOKEN: WILEY.

Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitis

Cameron, A., Giri, R., Begun, J., Wells, T., Bergot, A. S. and Thomas, R. (2023). Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitis. EULAR 2023 European Congress of Rheumatology, Milan, Italy, 31 May-3 June 2023. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2023-eular.1346

BASELINE CYTOKINE LEVELS AND MICROBIOME SIGNATURES ARE ASSOCITED WITH CLINICAL RESPONSE FOLLOWING USTEKINUMAB INDUCTION IN A MULTI-CENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY

An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Giri, Rabina, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). BASELINE CYTOKINE LEVELS AND MICROBIOME SIGNATURES ARE ASSOCITED WITH CLINICAL RESPONSE FOLLOWING USTEKINUMAB INDUCTION IN A MULTI-CENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.

POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY

An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Hai Pham, , Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.

REDUCTION OF BOWEL WALL THICKNESS AND DOPPLER SIGNALS AS EARY AS 36 HOURS PREDICTS CORTICOSTEROID RESPONSE IN A MULTI-CENTRE PROSPECTIVE COHORT OF ACUTE SEVERE ULCERATIVE COLITIS: USUC STUDY INCLUDING GENIUS COHORT

An, Yoon-Kyo, Fernandes, Richard, Lindsay, Niamh, Khoo, Emi, Pham, Hai, Wong, Kam Fai, Thin, Lena, Goodsall, Thomas, Bryant, Robert V., Wright, Emily K., Smith, Rebecca, Friedman, Antony and Begun, Jakob (2023). REDUCTION OF BOWEL WALL THICKNESS AND DOPPLER SIGNALS AS EARY AS 36 HOURS PREDICTS CORTICOSTEROID RESPONSE IN A MULTI-CENTRE PROSPECTIVE COHORT OF ACUTE SEVERE ULCERATIVE COLITIS: USUC STUDY INCLUDING GENIUS COHORT. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.

WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL

Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.

THE INTERPLAY OF IL-23, PROBIOTIC AND PATHOBIONT BACTERIA IN THE PATHOGENESIS OF ILEITIS AND SPONDYLOARTHRITIS IN THE SKG MOUSE MODEL

Bergot, Anne-Sophie, Cai, Benjamin, Giri, Rabina, Cameron, Miss Amy, Duggan, Emily, Lim, Kai, Rehaume, Linda, Morrison, Mark, Begun, Jakob and Thomas, Ranjeny (2023). THE INTERPLAY OF IL-23, PROBIOTIC AND PATHOBIONT BACTERIA IN THE PATHOGENESIS OF ILEITIS AND SPONDYLOARTHRITIS IN THE SKG MOUSE MODEL. HOBOKEN: WILEY.

Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort

An, Y. K., Lindsay, N., Allan, N., Khoo, E., Fernandes, R., Amiss, A., Pham, H., Wong, K. F., Ooi, S. Y., Thin, L., Lightowler, D., Connor, S. J., Williams, A. J., De Cruz, P., Suen, C. Li Wai, Kariyawasam, V., Mitrev, N., Ghaly, S., Andrews, J. M., Christensen, B., Sparrow, M. P., White, L. S., Bryant, R. V., Ding, N., Leong, R., Van Langenberg, D., Seltenreich, H., Subramaniam, K., Radford-Smith, G. and Begun, J. (2023). Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort. OXFORD: OXFORD UNIV PRESS.

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

An, Y. K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A. and Begun, J. (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. OXFORD: OXFORD UNIV PRESS.

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. OXFORD: OXFORD UNIV PRESS.

Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel disease

Moniruzzaman, M., Rewatkar, P., Begun, J. and Popat, A. (2023). Enhancing the efficacy of cannabidiol using protein nanoparticles to treat inflammatory bowel disease. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0167

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

An, Y.K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A., Begun, J. and Gastroenterology Network of Intestinal Ultrasound (GENIUS) (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0744

Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort

An,Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Amiss, Anna, Moniruzzaman, Md, Fernandes, Richard , Ooi, Soong-Yuan J., Thin, Lena W.Y., Mstj, Daniel Lightowler, Connor, Susan, Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nicola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren, Bryant, Robert, Ding, Nik S., Leong, Rupert W., Van Langenberg, Daniel R., Seltenreich, Hans, Subramaniam, Kavitha, Radford-Smith, Graham and Begun, Jakob (2022). Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9–11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.15953

So many therapies—So little data: How to choose? Session two summary

Begun, Jakob (2021). So many therapies—So little data: How to choose? Session two summary. Takeda IBD Symposium IBD 2020: Right Therapy, Right Patient, Right Time#Choosing Wisely, Online, 5 September 2020. Richmond, VIC Australia: Wiley-Blackwell. doi: 10.1111/jgh.15450

Curdlan-induced Villous Permeability, Luminal Pathobiont Translocation to the Ileal Crypts, Ileitis and Arthritis Are Mitigated by Clostridia in Colonised Germ-free SKG Mice

Bergot, Anne-Sophie, Giri, Rabina, Cameron, Amy, Duggan, Emily, Loayza, Jeimy Jimenez, Morrison, Mark, Rehaume, Linda, Begun, Jakob and Thomas, Ranjeny (2020). Curdlan-induced Villous Permeability, Luminal Pathobiont Translocation to the Ileal Crypts, Ileitis and Arthritis Are Mitigated by Clostridia in Colonised Germ-free SKG Mice. Annual Meeting of the American-College-of-Rheumatology (ACR), Electr Network, Nov 05-09, 2020. HOBOKEN: WILEY.

Investigating the role of bioactives produced by gut bacteria to modulate immune response in inflammatory bowel disease

Giri, R., Shamsunnahar, K., Salim, A., Capon, R., Morrison, M., Cuiv, P. O. and Begun, J. (2020). Investigating the role of bioactives produced by gut bacteria to modulate immune response in inflammatory bowel disease. 15th Congress of ECCO, Vienna, Austria, 12-15 February 2020. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjz203.035

Endoscopic balloon dilatation is safe and has a high success rate in patients with stricturing Crohn's disease

Lim, E., Thai, M., Hendy, P., Alchlaihawi, M., Leong, R., Connor, S., Ng, W., Gu, B., van Langenberg, D., Thin, L., Schulberg, J., Kamm, M., Gilmore, R., Taylor, K., Sallis, O., Andrews, J., Daker, C., Barclay, M., Wark, G., Ghaly, S., Begun, M., Krishnaprasad, K. and Begun, J. (2019). Endoscopic balloon dilatation is safe and has a high success rate in patients with stricturing Crohn's disease. 14th Congress of ECCO, Copenhagen, Denmark, 6-9 March 2019. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjy222.647

Effectiveness of fecal calprotectin testing to identify patients with organic gastrointestinal diseases: a systematic review and diagnostic meta-analysis

An, Y., Prince, D., Gardiner, F., Linedale, E., Andrews, J., Connor, S. and Begun, J. (2019). Effectiveness of fecal calprotectin testing to identify patients with organic gastrointestinal diseases: a systematic review and diagnostic meta-analysis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “The Universe Within”, Adelaide, South Australia, 8-10 September 2019. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.14803

Investigating the role of bioactives produced by gut bacteria to modulate immune response in inflammatory bowel disease

Giri, R., Cuiv, P. O. and Begun, J. (2019). Investigating the role of bioactives produced by gut bacteria to modulate immune response in inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “The Universe Within”, Adelaide, Australia, 8-10 September 2019. Hoboken, NJ, United States: Wiley-Blackwell. doi: 10.1111/jgh.14800

On the role of inflammation in acute paracetamol injury

Alabbas, Saleh, Movva, Ramya, Begun, Jakob, Florin, Timothy and Oancea, Iulia (2019). On the role of inflammation in acute paracetamol injury. International Liver Congress, Vienna Austria, 10-14 April 2019. Amsterdam, Netherlands: Elsevier. doi: 10.1016/S0618-8278(19)30823-0

Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study

Haifer, C., Srinivasan, A., Menon, S., An, Y., Picardo, S., Van Langenberg, D., Begun, J., Ghaly, S. and Thin, L. (2019). Switching Australian patients with moderate to severe inflammatory bowel disease from originator infliximab to biosimilar Inflectra: Interim results from a multicenter parallel cohort study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “The Universe Within”, Adelaide, SA, Australia, 8–10 September 2019. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.14801

Enteric microbiota shape the inflammatory response in mice with a Muc2 misfolding mutation

Wang, R., Giri, R., Moniruzzaman, M., Tong, H., Wong, K. Y., Begun, J., McGuckin, M. A. and Hasnain, S. Z. (2018). Enteric microbiota shape the inflammatory response in mice with a Muc2 misfolding mutation. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) “Gut Matters”, Brisbane, QLD, Australia, 8-10 September 2018. Richmond, VIC, Australia: John Wiley & Sons.

Predictors in inflammatory bowel disease: Looking into the magic ball: session one summary

Begun, Jakob (2018). Predictors in inflammatory bowel disease: Looking into the magic ball: session one summary. The Takeda Symposium, Melbourne, VIC Australia, 17 – 18 March 2018. Richmond, VIC Australia: Wiley-Blackwell. doi: 10.1111/jgh.14415

Crohn's colitis care (CCCare): development and testing of a bespoke cloud-based clinical management system for inflammatory bowel disease (IBD)

Krishnaprasad, K., Walsh, A., Begun, J., Bell, S., Carter, D., Grafton, R., Sechi, A., Sewell, K., McMahon, A., Connor, S., Radford-Smith, G. and Andrews, J. (2018). Crohn's colitis care (CCCare): development and testing of a bespoke cloud-based clinical management system for inflammatory bowel disease (IBD). 13th Congress of ECCO, Vienna, Austria, 14-17 February 2018. Oxford, United Kingdom: Oxford University Press.

Positioning biologics-A case-based discussion: Ustekinumab

Begun, Jakob (2018). Positioning biologics-A case-based discussion: Ustekinumab. Personalizing Inflammatory Bowel Disease Treatment, Melbourne, Australia, 17-18 March 2018. Richmond, VIC, Australia: Wiley-Blackwell. doi: 10.1111/jgh.14423

Selectively targeting the gut in inflammatory bowel disease: session four summary

Begun, Jakob (2018). Selectively targeting the gut in inflammatory bowel disease: session four summary. Personalizing Inflammatory Bowel Disease Treatment, Melbourne, Australia, 17-18 March 2018. Richmond, VIC, Australia: Wiley-Blackwell. doi: 10.1111/jgh.14430

A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Youth Living with Inflammatory Bowel Disease and Depression

Ewais, T., Begun, J., Barclay, J., Tefay, M. and Tremellen, A. (2017). A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Youth Living with Inflammatory Bowel Disease and Depression. American Psychiatric Association 2017 Annual Meeting, San Diego, 20-24 May 2017. London, United Kingdom: Sage Publications .

Endoscopic balloon dilatation has a high success rate and appears to reduce the need for surgery in patients with stricturing Crohn's disease

Lim, E., Thai, M., Hendy, P., Alchlaihawi, M., Leong, R. and Begun, J. (2017). Endoscopic balloon dilatation has a high success rate and appears to reduce the need for surgery in patients with stricturing Crohn's disease. Australian Gastroenterology Week: Precision Medicine in Gastroenterology, Gold Coast, Queensland, 20-22 August 2017. Richmond, VIC, Australia: Wiley-Blackwell.

Factors influencing the need for endoscopic intervention in esophageal meat bolus impaction: a retrospective, multicenter study

Cheng, D., Lee, R., Lee, A., Begun, J. and St John, A. (2017). Factors influencing the need for endoscopic intervention in esophageal meat bolus impaction: a retrospective, multicenter study. Australian Gastroenterology Week: Precision Medicine in Gastroenterology, Gold Coast, Queensland, 20-22 August 2017. Richmond, VIC, Australia: Wiley-Blackwell.

Role of anti-inflammatory gut bioactives in the modulation of immune response in Crohn's disease

Giri, R., Cuiv, P. O. and Begun, J. (2017). Role of anti-inflammatory gut bioactives in the modulation of immune response in Crohn's disease. Gastroenterological Society of Australia Australian Gastroenterology Week Precision Medicine in Gastroenterology, Gold Coast, QLD Australia, 20–22 August 2017. Richmond, VIC Australia: Wiley.

Subsets of innate lymphoid cells in acute liver injury

Alabbas, S. Y., Mowa, R., Purdon, A. S., Begun, J., Florin, T. H. and Oancea, I. (2017). Subsets of innate lymphoid cells in acute liver injury. Australian Gastroenterology Week: Precision Medicine in Gastroenterology, Gold Coast, Queensland, 20-22 August 2017. HOBOKEN: Wiley-Blackwell.

Targeting interleukin-23(p19) secretion from intestinal epithelial cells to improve intestinal barrier integrity in inflammatory bowel disease

Wang, R., Lourie, R., Tong, H., Giri, R., Schreiber, V., Begun, J., Florin, T., McGuckin, M. A. and Hasnain, S. Z. (2017). Targeting interleukin-23(p19) secretion from intestinal epithelial cells to improve intestinal barrier integrity in inflammatory bowel disease. Gastroenterological Society of Australia Australian Gastroenterology Week Precision Medicine in Gastroenterology, Gold Coast, QLD Australia, 20–22 August 2017. Richmond, VIC Australia: Wiley.

Inflammatory bowel disease in the clinic: escalation and de-escalation of therapy: a longitudinal case-based discussion

Begun, Jakob (2016). Inflammatory bowel disease in the clinic: escalation and de-escalation of therapy: a longitudinal case-based discussion. The Takeda Symposium, Sydney, NSW Australia, 13-14 February 2016. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/jgh.13348

Bacterial activation of thioguanine results in lymphocyte independent improvement in murine colitis

Oancea, I., Das, I., de Carcer, D. Aguirre, Movva, R., Schreiber, V., Yang, Y., Proctor, M., Wang, R., Sheng, Y., Lobb, M., Cuiv, P. O., Duley, J. A., Begun, J. and Florin, T. H. J. (2016). Bacterial activation of thioguanine results in lymphocyte independent improvement in murine colitis. 11th Congress of ECCO - European Crohn’s and Colitis Organisation, Amsterdam, Netherlands, 16-19 March 2016. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjw019.177

Alleviation of Acute Drug-Induced Liver Injury Following Acetaminophen Overdose by Therapeutic Blockade of E-Selectin in Preclinical Mouse Model

Oancea, Iulia, Barbier, Valerie, Chee, David, Lourie, Rohan, Movva, Ramya, Proctor, Martina A., Begun, Jakob, Magnani, John L., Florin, Timothy H. and Winkler, Ingrid (2016). Alleviation of Acute Drug-Induced Liver Injury Following Acetaminophen Overdose by Therapeutic Blockade of E-Selectin in Preclinical Mouse Model. 57th Annual Meeting and Residents Fellow Conference of the Society for Surgery of the Alimentary Tract (SSAT) / 52nd Annual Meeting on Digestive Disease Week (DDW) / Meeting of the American-Gastroenterological-Association (AGA), San Diego, CA United States, 21-24 May 2016. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(16)33483-7

An inhibitor of Wnt protein production improves host control of Listeria monocytogenes

Tran, T. T., Andrades, M. G., Nguyen, T. T. K., Wyer, O., Kling, J. C., Begun, J. and Blumenthal, A. (2016). An inhibitor of Wnt protein production improves host control of Listeria monocytogenes. ICI 2016 International Congress of Immunology, Melbourne, VIC, Australia, 21-26 August 2016. Weinheim, Germany: Wiley - VCH Verlag. doi: 10.1002/eji.201670200

Clinical presentation of IBD diagnosed after age 60

Shukla, D., Begun, J. and Florin, T. (2016). Clinical presentation of IBD diagnosed after age 60. Gastroenterological Society of Australia, Australian Gastroenterology Week 2016, Adelaide, South Australia, Australia, 10–12 October 2016. HOBOKEN: WILEY-BLACKWELL. doi: 10.1111/jgh.13522

High fat diets induce colonic epithelial cell stress and inflammation that is reversed by IL-22

Gulhane, M., Lourie, R., Tong, H., Kang, A., Schreiber, V., Magor, G., Denman, S., Begun, J., Florin, T., Perkins, A., O Cuiv, P., Mcguckin, M. and Hasnain, S. Z. (2016). High fat diets induce colonic epithelial cell stress and inflammation that is reversed by IL-22. ICI 2016 International Congress of Immunology, Melbourne, Australia, 21–26 August 2016. Weinheim, Germany: Wiley. doi: 10.1002/eji.201670200

Severe bacterial infections with vedolizumab therapy: 3 illustrative cases

Szetoo, S. W., Hume, G., De Cruz, P. and Begun, J. (2016). Severe bacterial infections with vedolizumab therapy: 3 illustrative cases. Gastroenterological Society of Australia, Australian Gastroenterology Week 2016, Adelaide, South Australia, Australia, 10–12 October 2016. HOBOKEN: WILEY-BLACKWELL. doi: 10.1111/jgh.13522

The burden of illness among adolescents and young adults with inflammatory bowel disease

Duffy, K. and Begun, J. (2016). The burden of illness among adolescents and young adults with inflammatory bowel disease. Gastroenterological Society of Australia, Australian Gastroenterology Week 2016, Adelaide, South Australia, Australia, 10–12 October 2016. HOBOKEN: WILEY-BLACKWELL. doi: 10.1111/jgh.13522

The incidence of 30-day adverse events after colonoscopy in an IBD population

An, Y. K., Wong, J., You, I. S., Mortimore, M., Hewett, D. G., Appleyard, M. N. and Begun, J. (2016). The incidence of 30-day adverse events after colonoscopy in an IBD population. Gastroenterological Society of Australia, Australian Gastroenterology Week 2016, Adelaide, South Australia, Australia, 10–12 October 2016. HOBOKEN: WILEY-BLACKWELL. doi: 10.1111/jgh.13522

Thiopurine Mediated Chemoprevention of Colitis-Associated Colorectal Dysplasia

Jose, Beulah, Lourie, Rohan, Schreiber, Veronika, Florin, Timothy H., Oancea, Iulia and Begun, Jakob (2016). Thiopurine Mediated Chemoprevention of Colitis-Associated Colorectal Dysplasia. 57th Annual Meeting and Residents Fellow Conference of the Society for Surgery of the Alimentary Tract (SSAT) / 52nd Annual Meeting on Digestive Disease Week (DDW) / Meeting of the American Gastroenterological Association (AGA57th Annual Meeting and Residents Fellow Conference of the Society for Surgery of the Alimentary Tract (SSAT) / 52nd Annual Meeting on Digestive Disease Week (DDW) / Meeting of the American-Gastroenterological-Association (AGA), San Diego, CA United States, 21-24 May 2016. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(16)33291-7

Malnutrition and quality of life among inflammatory bowel disease outpatients

Pulley, J., Todd, A., Flatley, C. and Begun, J. (2015). Malnutrition and quality of life among inflammatory bowel disease outpatients. Gastro 2015 GESA‐AGW and WGO International Congress, Gastroenterological Society of Australia Australian Gastroenterology Week 2015, Brisbane, QLD Australia, 28 September‐2 October 2015. Richmond, VIC Australia: John Wiley and Sons. doi: 10.1111/jgh.13096